Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
CHESTERBROOK, Pa., Dec. 27, 2023 (GLOBE NEWSWIRE) — Trevena Inc. (“Trevena” or the “Company”) (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered into definitive agreements for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants in lieu thereof) of Trevena and warrants to purchase up to an aggregate of 2,779,906 shares of common stock of Trevena, at a purchase price of $0.70 per share (or pre-funded warrant in lieu thereof) and associated warrant in a private placement, for expected gross proceeds to the Company of approximately $1.946 million (the “private placement”).
Related news for (TRVN)
- Trevena Publicizes TRV045 Preclinical Data
- Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
- Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting
- Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings